Verrica Pharmaceuticals Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Verrica Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 0.00 shares.
- Verrica Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-12-31 was -38.25K shares.
- Verrica Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-09-30 was 0.00 shares.
- Verrica Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-06-30 was 36.00K shares, a 350.00% increase year-over-year.
- Verrica Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 4.25K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | |
| 2024-12-31 | -38.25K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | 4.25K shares 10-K · filed 2026-03-11 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | |
| 2024-06-30 | 36.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | |
| 2024-03-31 | 6.50K shares 10-Q · filed 2024-05-13 | |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | |
| 2023-06-30 | 8.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | |
| 2023-03-31 | 0.00 shares 10-Q · filed 2023-05-09 | |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | |
| 2022-03-31 | 0.00 shares 10-Q · filed 2022-05-09 | |
| 2021-09-30 | 4.33K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | |
| 2021-06-30 | 39.47K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | |
| 2021-03-31 | 240.00 shares 10-Q · filed 2022-05-09 | |
| 2020-09-30 | 51.05K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | |
| 2020-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | |
| 2020-03-31 | 7.50K shares 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |